v3.26.1
Information Concerning the Group's Consolidated Operations - Additional Information (Detail) - USD ($)
$ in Thousands
 3 Months Ended 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Jun. 30, 2026
Jun. 30, 2025
Consolidated operations [line items]        
Increase (decrease) in foreign exchange gains $ (2,400)   $ (400)  
Decrease /increase in financial Expenses 16,700 $ 16,700 22,300 $ 22,300
Increase (decrease) in foreign exchange losses (16,400)   (22,800)  
Increase in selling, general and administrative expenses 700 700 1,500 1,500
Increase in other income     600 600
Revenues 5,229 16,725 $ 11,006 $ 27,380
Effective income tax rate     (0.20%) 0.00%
Decrease in revenues     $ 16,400  
Increase in research and development expense 1,900 1,900 7,200 $ 7,200
Net financial gain (loss) improved     27,300  
Increase in financial income     5,000 5,000
Decrease in financial income 800 800    
Net financial gain (loss) 1,727 (14,150) 9,176 (18,098)
Increase in non-cash gains recognized from fair value measurements     7,000  
Decrease in interest income earned on cash, cash equivalents and financial assets 600      
Increase (decrease) in interest income earned on cash, cash equivalents and financial assets     (1,700)  
Gain in fair value recognized in profit and loss 2,255 $ 0 8,761 1,766
European Investment Bank Warrants [Member]        
Consolidated operations [line items]        
Gain in fair value recognized in profit and loss 2,300   8,700 1,200
Research and development expenses [member]        
Consolidated operations [line items]        
Increase in personnel expenses 800   4,500  
Increase in depreciation and amortization expenses 600   1,000  
Increase in purchases and external expenses $ 1,700   3,700  
Astra Zeneca Ireland [Member] | Joint Collaboration and Research Agreement [Member]        
Consolidated operations [line items]        
Revenues     $ 10,700 $ 26,900